Metrics to compare | RUBI | Peers Peers - average of corresponding metrics from companies closely matching RUBI: ADDTB, VELJAN, NEULANDLAB, LAURUSLABS, 7711 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRUBIPeersSector |
|---|---|---|---|---|
P/E Ratio | 95.1x | 32.2x | −0.4x | |
PEG Ratio | 1.21 | 0.32 | 0.00 | |
Price/Book | 21.3x | 4.2x | 2.6x | |
Price / LTM Sales | 14.2x | 4.1x | 3.1x | |
Upside (Analyst Target) | 14.3% | 7.7% | 55.6% | |
Fair Value Upside | Unlock | 2.4% | 7.8% | Unlock |
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies. The company was incorporated in 1999 and is headquartered in Mumbai, India.